Provided by Tiger Trade Technology Pte. Ltd.

Lexaria Bioscience Corp

2.88
-0.2100-6.80%
Post-market: 2.87-0.0134-0.47%19:30 EDT
Volume:81.26K
Turnover:240.01K
Market Cap:6.07M
PE:-0.56
High:3.24
Open:3.18
Low:2.80
Close:3.09
52wk High:21.60
52wk Low:2.80
Shares:2.11M
Float Shares:2.06M
Volume Ratio:1.80
T/O Rate:3.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.1429
EPS(LYR):-9.9189
ROE:-162.77%
ROA:-81.30%
PB:1.28
PE(LYR):-0.29

Loading ...

Jun 08, 2024

Correspondence

Form CORRESP - Correspondence
Jun 03, 2024

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Apr 30, 2024

Major Issues Report

Form 8-K - Current report
Apr 24, 2024

Major Issues Report

Form 8-K - Current report
Apr 09, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 21, 2024

Major Issues Report

Form 8-K - Current report
Mar 18, 2024

Correspondence

Form CORRESP - Correspondence
Mar 15, 2024

Major Issues Report

Form 8-K - Current report
Mar 12, 2024

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Mar 01, 2024

Major Issues Report

Form 8-K - Current report
Feb 16, 2024

Major Issues Report

Form 8-K - Current report
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 30, 2024

Major Issues Report

Form 8-K - Current report
Jan 24, 2024

Major Issues Report

Form 8-K - Current report
Jan 19, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Jan 13, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jan 05, 2024

Major Issues Report

Form 8-K - Current report
Dec 07, 2023

Correspondence

Form CORRESP - Correspondence
Nov 30, 2023

Public Prospectus

Form S-1 - General form for registration of securities under the Securities Act of 1933
Nov 21, 2023

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]